We've changed the way you complete courses
In response to user feedback we have simplified the way courses can be completed.
Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.
Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.
Once you have completed all of the topics in a module an assessment will be provided for you.
Complete all the assessments to finish the course.
Welcome to the course on cardiovascular health and diabetes
Cardiovascular health is one of the most significant and challenging aspects of management for type 1 and type 2 diabetes. The first module in this course presents an overview of related historic and contemporary study data and examines what this can tell us about cardiovascular risk for people with diabetes. Module 2 delves deeper into the data, interrogating the sometimes controversial evidence major trials have provided as to the impact of intensive glucose control on cardiovascular outcomes.
The range of glucose-lowering drugs available to physicians has expanded greatly since the early landmark studies in this field. New regulations have also changed the way cardiovascular risk is factored into contemporary trial design. With these changes in mind, module 3 looks at the cardiovascular aspects of the outcomes from trials of the newer diabetes therapies.
A wealth of evidence now exists to demonstrate the benefits of lipid-lowering treatments for cardiovascular health. Module 4 takes you through several major meta-analyses of trial data on this aspect of care. Meanwhile, module 5 turns the spotlight on blood pressure-lowering trials, together with an analysis of what the recently published ASCEND study tells us about the use of aspirin for primary prevention in diabetes.
In module 6 we cast a look back to the 1990’s, when the Steno-2 trial first investigated the benefits of intensive treatment to target a range of cardiovascular risk factors in type 2 diabetes. Looking back over more than two decades of follow-up, Steno-2’s message is clear: even without the novel treatments available to us today, multifactorial intervention at an early stage works.
Module 7 brings us back to the present with an overview of cardiovascular outcome data from two recent trials that deliberately trained their sights on the use of SGLT-2 inhibitors in patients with heart failure – EMPEROR-Reduced (which studied empagliflozin) and DAPA-HF (dapagliflozin).
Once enrolled on a course you can access the content in any order you wish, simply browse the course using the ‘CONTENT AND YOUR PROGRESS’ section on this page.
If at any time you need help finding the next step to complete just click the green question mark in the bottom right of the screen for directions.